中肿4项鼻咽癌口头报告引领2023 ASCO头颈部肿瘤重磅研究

编者按：一年一度的临床肿瘤学界奥林匹克盛会——美国临床肿瘤学会（ASCO）年会将于当地时间6月2～6日在芝加哥举行。日前，ASCO会议官网公布了此次年会的日程和摘要题目。头颈部肿瘤领域多项重磅研究即将公布，其中，中山大学肿瘤防治中心共有4项鼻咽癌研究入选口头摘要专场（Oral Abstract Session）和壁报交流专场（Poster Discussion Session），可喜可贺！本文带您提前速览摘要题目。

口头摘要专场（Oral Abstract Session）

Abstract: 6000

Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial.

N2-3鼻咽癌同步放化疗后辅助顺铂 + 吉西他滨 vs. 顺铂 + 5-氟尿嘧啶化疗：一项多中心、开放标签、随机、对照、Ⅲ期试验

Presenter: 唐林泉教授 | 中山大学肿瘤防治中心

GMT+8 21:00

Abstract: 6001

Induction chemotherapy plus radiotherapy alone versus cisplatin-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: An open-label, non-inferiority, randomized phase 3 trial.

局部晚期鼻咽癌的诱导化疗联合放疗 vs. 基于顺铂的同步放化疗：一项开放标签、非劣效性、随机Ⅲ期试验

Presenter: 陈明远教授 | 中山大学肿瘤防治中心

GMT+8 21:12

Abstract: LBA6002

PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM).

PD-1抑制剂信迪利单抗联合诱导化疗和同步放化疗（IC-CCRT）vs. IC-CCRT治疗局部晚期鼻咽癌（LANPC）：多中心、Ⅲ期、随机对照CONTINUUM试验

Presenter: 马骏教授 | 中山大学肿瘤防治中心

GMT+8 21:24

Abstract: 6003

Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab combined with weekly paclitaxel carboplatin in first-line in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible for cisplatin-based therapies.

评估度伐利尤单抗联合紫杉醇卡铂周方案一线治疗不符合基于顺铂治疗条件的复发/转移性头颈部鳞状细胞癌（R/M SCCHN）患者的疗效和安全性：多中心Ⅱ期FRAIL-IMMUNE试验的结果

Presenter: Jerome Fayette, MD, PhD | Centre Leon Bérard, Medical Oncology

GMT+8 22:00

Abstract: LBA6004

Phase 3 randomized study for evaluation of physician choice Rx and triple metronomic as second-line therapy in head and neck cancer (CRSF 2021-HN-001).

评估医生选择的Rx和三联节拍疗法作为头颈部肿瘤二线治疗的Ⅲ期随机研究（CRSF 2021-HN-001）

Presenter: Rushabh Kiran Kothari, MD | Narayana Multispeciality Hospital

GMT+8 22:12

Abstract: 6005

Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma.

双功能EGFR/TGFβ抑制剂BCA101联合帕博利珠单抗在复发性、转移性头颈部鳞状细胞癌患者中的剂量扩展研究结果

Presenter: Glenn J. Hanna, MD | Dana-Farber Cancer Institute

GMT+8 22:24

Abstract: 6006

Randomised phase III trial of the hypoxia modifier nimorazole added to radiotherapy with benefit assessed in hypoxic head and neck cancers determined using a gene signature (NIMRAD).

将低氧细胞放射增敏剂尼莫拉唑加入化疗的随机Ⅲ期试验：在应用一种基因特征所确定的缺氧头颈部肿瘤中的疗效评估

Presenter: David Thomson, MD, FRCR | The Christie NHS Foundation Trust

GMT+8 23:00

Abstract: 6007

Neoadjuvant nivolumab, paclitaxel, and carboplatin followed by response-stratified chemoradiation in locoregionally advanced HPV negative head and neck squamous cell carcinoma (HNSCC): The DEPEND trial.

局部晚期HPV阴性的头颈部鳞状细胞癌（HNSCC）接受新辅助纳武利尤单抗、紫杉醇和卡铂随后基于反应分层进行放化疗：DEPEND试验

Presenter: Ari Rosenberg, MD | University of Chicago

GMT+8 23:12

Abstract: 6008

Immuno-chemotherapy as single treatment modality for larynx preservation (ICoLP): Co-primary endpoints and safety results.

免疫化疗作为喉部保留的单一治疗方式（ICoLP）：共同主要终点和安全性结果

Presenter: Renata Ferrarotto, MD | Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center

GMT+8 23:24

壁报交流专场（Poster Discussion Session）

Abstract: 6009 | Poster Bd #: 1

Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).

Ⅲ期JUPITER-02的最终总生存分析：特瑞普利单抗对比安慰剂分别联合吉西他滨和顺铂作为复发或转移性鼻咽癌（NPC）的一线治疗

Presenter: 麦海强教授 | 中山大学肿瘤防治中心

Abstract: 6010 | Poster Bd #: 2

NEOSPACE trial: Neoadjuvant pembrolizumab-gemcitabine-cisplatin followed by concurrent pembrolizumab-chemoradiation and maintenance pembrolizumab for stage IVA nasopharyngeal cancer (NPC).

NEOSPACE试验：对于IVA期鼻咽癌（NPC），帕博利珠单抗+吉西他滨+顺铂新辅助治疗随后同步帕博利珠单抗+放化疗和帕博利珠单抗维持治疗

Presenter: Edwin P Hui, MD | Department of Clinical Oncology, Prince of Wales Hospital

Abstract: 6011 | Poster Bd #: 3

Dual PD1 and CTLA4 immune checkpoint blockade and hypofractionated radiation in patients with salivary gland cancers.

PD-1和CTLA4双免疫检查点抑制剂和低分割放疗治疗唾液腺癌患者

Presenter: Cristina P. Rodriguez, MD | University of Washington

Abstract: 6012 | Poster Bd #: 4

Safety and efficacy of immune checkpoint inhibitor (ICI) naïve cohort from study of PDS0101 and pembrolizumab in HPV16-positive head and neck squamous cell carcinoma (HNSCC).

来自PDS0101和帕博利珠单抗治疗HPV 16阳性头颈部鳞状细胞癌的研究中，免疫检查点抑制初治队列的疗效和安全性

Presenter: Katharine Andress Rowe Price, MD | Department of Oncology, Mayo Clinic

Abstract: 6013 | Poster Bd #: 5

A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer.

CUE-101（一种新的HPV16 E7-pHLA-IL2-2-Fc融合蛋白）作为单药治疗和联合帕博利珠单抗用于复发/转移性HPV16+头颈部肿瘤患者的Ⅰ期剂量递增和扩展研究

Presenter: Christine H. Chung, MD | Moffitt Cancer Center

Abstract: 6014 | Poster Bd #: 6

Phase II trial of adjuvant de-escalated radiation + adjuvant nivolumab for intermediate-high risk P16+ oropharynx cancer.

降阶辅助放疗+辅助纳武利尤单抗治疗中高危P16+口咽癌的Ⅱ期临床试验

Presenter: Heath Devin Skinner, MD, PhD | UPMC Hillman Cancer Center, Department of Radiation Oncology

Abstract: 6015 | Poster Bd #: 7

Correlation of CDKN2A genomic alterations with tumor response to palbociclib given before chemoradiation therapy (CRT) to patients with human papillomavirus (HPV)-negative, locally advanced head and neck squamous-cell carcinoma (LA-HNSCC): A single-arm, phase 2 trial.

对于人乳头状瘤病毒（HPV）阴性、局部晚期头颈部鳞状细胞癌（LA-HNSCC）患者，CDKN2A基因组改变与对放化疗（CRT）前给予的帕博西林的肿瘤反应的相关性：一项单臂Ⅱ期试验

Presenter: Peter John Oppelt, MD | Washington University School of Medicine

Abstract: 6016 | Poster Bd #: 8

Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with pembrolizumab and carboplatin as first-line treatment of recurrent or metastatic head and neck squamous-cell carcinoma (RM-HNSCC): A single-arm, phase 2 trial.

PARP抑制剂奥拉帕利联合帕博利珠单抗和卡铂作为复发或转移性头颈部鳞状细胞癌（RM-HNSCC）的一线治疗：一项单臂Ⅱ期试验

Presenter: Jared Cohen, MD | Washington University Siteman Cancer Center

Abstract: 6017 | Poster Bd #: 9

Enfortumab vedotin in the previously treated advanced head and neck cancer (HNC) cohort of EV-202.

Enfortumab vedotin在EV-202研究既往治疗的晚期头颈部肿瘤（HNC）队列中的应用

Presenter: Paul Swiecicki, MD | Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan Medical School

Abstract: 6018 | Poster Bd #: 10

Neoadjuvant nivolumab alone or in combination with relatlimab or ipilimumab in resectable head and neck squamous cell carcinoma (HNSCC).

新辅助纳武利尤单抗单独或联合relatlimab或伊匹木单抗治疗对于可切除头颈部鳞状细胞癌（HNSCC）的疗效

Presenter: Robert L. Ferris, MD, PhD | Hillman Cancer Center

Abstract: 6019 | Poster Bd #: 11

Neoadjuvant cemiplimab with platinum-doublet chemotherapy and cetuximab to de-escalate surgery and omit adjuvant radiation in locoregionally advanced head & neck squamous cell carcinoma (HNSCC).

对于局部晚期头颈部鳞状细胞癌（HNSCC），新辅助cemiplimab联合含铂双药化疗和西妥昔单抗可降阶手术并省略辅助放疗

Presenter: Lara Dunn, MD | Memorial Sloan Kettering Cancer Center

Abstract: 6020 | Poster Bd #: 12

The Quarterback trials: A phase 2 series of sequential studies of induction chemotherapy followed by reduced dose chemoradiation for human papillomavirus positive oropharynx cancer.

Quarterback试验：对人乳头状瘤病毒阳性口咽癌进行诱导化疗后再减少剂量放化疗的Ⅱ期系列序列研究

Presenter: Marshall R. Posner, MD | Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai